Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$27,000.00

Unveiling Novel Therapeutic Targets for Microglial Modulation in Alzheimer’s Disease: the TREM2:ABI3 Interaction

FY 2024-25

Summary
Alzheimer Disease (AD) is a brain disorder that currently affects millions of people. AD causes memory loss and difficulty with everyday tasks. Although some drugs can slow memory loss, they arent very effective. Scientists know that AD is caused by the buildup of misfolded proteins, like amyloid beta, and that these harmful proteins cause changes in microglia. Microglia are the brain resident immune cells. Microglia usually help protect the brain by clearing away unwanted proteins, but in AD, they do not function properly.This project explores two major regulators of microglial function in AD, TREM2 and ABI3.TREM2 is a protein on the surface of microglia that recognizes harmful debris and proteins. ABI3 works together with TREM2, but how they work together is not fully understood. We recently discovered that a specific variant in TREM2 might affect its function. We showed that the variant reduces intake of harmful proteins associated with AD risk and affects signalling within the cell. Interestingly, the effects of the variant depend on the presence of functional ABI3. While the results are clear in animal models, the proposed research aims to study how this genetic variant and its interaction with ABI3 might contribute to AD risk in humans with the ultimate goal of making new drugs to target the role of microglia in AD development.The research aims to i) create microglia expressing both forms of the variant using CRISPR editing and human stem cells, ii) study TREM2 activation in these cells, and iii) test microglia function in these cells.By better understanding why some people are more vulnerable to AD, this research could uncover new ways to improve microglial function and develop treatments that significantly slow memory loss in AD.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
529966
Name
Acheson Beatrice C
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Unveiling Novel Therapeutic Targets for Microglial Modulation in Alzheimer’s Disease: the TREM2:ABI3 Interaction
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Alzheimer’S Disease; Genetics; Ipsc; Microglia; Missense Variant; Neurodegeneration; Neuroimmunology; Phagocytosis; Signalling; Therapeutic Targets
Abstract
Alzheimer Disease (AD) is a brain disorder that currently affects millions of people. AD causes memory loss and difficulty with everyday tasks. Although some drugs can slow memory loss, they arent very effective. Scientists know that AD is caused by the buildup of misfolded proteins, like amyloid beta, and that these harmful proteins cause changes in microglia. Microglia are the brain resident immune cells. Microglia usually help protect the brain by clearing away unwanted proteins, but in AD, they do not function properly.This project explores two major regulators of microglial function in AD, TREM2 and ABI3.TREM2 is a protein on the surface of microglia that recognizes harmful debris and proteins. ABI3 works together with TREM2, but how they work together is not fully understood. We recently discovered that a specific variant in TREM2 might affect its function. We showed that the variant reduces intake of harmful proteins associated with AD risk and affects signalling within the cell. Interestingly, the effects of the variant depend on the presence of functional ABI3. While the results are clear in animal models, the proposed research aims to study how this genetic variant and its interaction with ABI3 might contribute to AD risk in humans with the ultimate goal of making new drugs to target the role of microglia in AD development.The research aims to i) create microglia expressing both forms of the variant using CRISPR editing and human stem cells, ii) study TREM2 activation in these cells, and iii) test microglia function in these cells.By better understanding why some people are more vulnerable to AD, this research could uncover new ways to improve microglial function and develop treatments that significantly slow memory loss in AD.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Acheson, Beatrice C
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~